Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alginate and lifestyle changes in gastro-oesophageal reflux disease
ISRCTN16072024Phase 4Active, not recruiting
- Sponsor
- Reckitt
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial in gastroesophageal reflux disease (GERD) comparing Alginate + lifestyle consultation with Omeprazole (2 arms). Primary endpoint: Change in reflux symptom severity at 4 weeks. Started Oct 2025; status: active, not recruiting.
02
Drugs
alginic acidomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on ISRCTN16072024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16072024.